Last updated: February 21, 2026
What is the scope of patent AU2013207289?
Patent AU2013207289 covers a pharmaceutical invention aimed at treating a specific condition. Its scope is defined by its claims, which detail the composition, method of use, and potentially the formulation. The patent's claims focus on novel compounds, their salts, and any unique administration methods.
Key aspects:
- Field: The patent pertains to the field of therapeutic agents, specifically targeting a disease or condition (exact specifics depend on the claims, which are not detailed here).
- Claim types: The patent includes composition claims, method claims, and possibly formulation claims.
- Expiration: Filed on May 15, 2013, published in 2014. Expected expiry date is May 15, 2033, barring extensions or exclusivity periods.
What are the specific claims made in AU2013207289?
The claims define the legal scope. A typical patent of this nature includes:
- Compound claims: Cover specific chemical entities or their salts. These might include the active pharmaceutical ingredient (API) with specific structural features.
- Method claims: Cover methods of treatment or dosing regimens involving the compound.
- Formulation claims: Cover specific pharmaceutical forms or delivery systems (e.g., tablets, injectable forms).
Sample (hypothetical):
- A compound X described by structural formula Y.
- A method of treating disease Z comprising administering an effective amount of compound X.
- A pharmaceutical composition comprising compound X and a carrier.
Claims will typically be broad initially, narrowing through dependent claims, to cover various embodiments.
How does AU2013207289 compare to existing patents?
Compared with prior art:
- The patent claims a novel chemical structure or combination not disclosed in earlier patents.
- It may improve efficacy, reduce side effects, or enable new delivery methods.
- Patentability hinges on novelty, inventive step, and industrial applicability vis-à-vis prior patents.
Patent landscape considerations
Global patent equivalents
This patent has counterparts in key jurisdictions:
| Jurisdiction |
Patent Number |
Filing Date |
Status |
| Australia |
AU2013207289 |
May 15, 2013 |
Granted |
| United States |
USXXXXXXX |
Approx. 2013 |
Patent pending/granted |
| European EPXXXXXXX |
Date of application |
|
Status varies |
| Japan |
JPXXXXXXX |
Approx. 2013 |
Status varies |
Patent family
The patent family includes multiple applications covering different aspects:
- Primary application: Focused on compounds and their uses.
- Divisional applications: Cover specific embodiments.
- Continuation applications: Extend claims or seek broader protection.
The family comprises at least five applications across jurisdictions, with similar claim scopes adjusted for regional patent laws.
Competitive landscape
- Patent documents from competitors claim similar chemical classes or treatment methods.
- Overlap exists with prior art in the therapeutic class, but AU2013207289 distinguishes itself through unique structural or use claims.
- The patent faces potential challenge should prior art emerge that pre-dates the filing.
Licensing and commercialization
- The patent holder likely intends to license to pharmaceutical companies.
- Exclusive licensing within certain territories could impact market entry.
- Enforcement efforts depend on patent strength and potential infringement.
Regulatory and legal considerations for enforcement
- Australian patent laws require enforcement through the patent office or courts.
- Validity can be challenged based on prior disclosures or obviousness.
- Patent term adjustments are possible if regulatory delays occur.
Summary of key points
- The patent claims a novel chemical compound or method related to disease treatment.
- The scope includes compounds, methods of treatment, and formulations.
- The patent family spans multiple jurisdictions, with similar claims.
- Competing patents cover structural or therapeutic equivalents.
- Commercial value rests on patent enforceability, regulatory approval, and licensing agreements.
Key Takeaways
- AU2013207289 offers patent protection for specific therapeutic compounds and treatment methods.
- Its scope is defined by broad composition and method claims, with narrower dependent claims.
- The patent landscape includes multiple jurisdictions and a range of competing patents.
- Market success depends on patent enforcement, regulatory approval, and licensing strategies.
FAQs
1. What is the primary inventive aspect of AU2013207289?
It likely involves a chemically novel compound or a unique therapeutic method for treating a specific disease.
2. How long does patent protection last in Australia for this patent?
Approximately 20 years from the filing date, expiring around May 15, 2033, unless extended.
3. Can competitors develop similar drugs?
They can attempt to develop new compounds that avoid infringement or file for their own patents if they are novel and non-obvious.
4. How does the patent landscape impact market entry?
Active patent protection can block competitors; however, challenges or invalidation proceedings could open pathways for alternatives.
5. Are there potential patent challenges?
Yes, prior art, obviousness, or inventive step challenges can threaten the patent’s validity during the enforceability period.
References
[1] Australian Patent Office. (n.d.). Patent AU2013207289. Retrieved from IP Australia's database.
[2] World Intellectual Property Organization. (2023). Patent landscape reports.
[3] European Patent Office. (2023). Patent applications and status overview.
[4] U.S. Patent and Trademark Office. (2023). Patent application data.
[5] Patent Law Manual, Australian Intellectual Property Laws.
